<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/B130E518-10A0-41F9-9139-D0A49B449623"><gtr:id>B130E518-10A0-41F9-9139-D0A49B449623</gtr:id><gtr:name>Sarissa Biomedical Limited</gtr:name><gtr:address><gtr:line1>ARGENT HOUSE , 5 GOLDINGTON ROAD</gtr:line1><gtr:city>BEDFORD</gtr:city><gtr:postCode>MK40 3JY</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B130E518-10A0-41F9-9139-D0A49B449623" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>B130E518-10A0-41F9-9139-D0A49B449623</gtr:id><gtr:name>Sarissa Biomedical Limited</gtr:name><gtr:address><gtr:line1>ARGENT HOUSE , 5 GOLDINGTON ROAD</gtr:line1><gtr:city>BEDFORD</gtr:city><gtr:postCode>MK40 3JY</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>15000.0</gtr:offerGrant><gtr:projectCost>25900.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F3A630B1-725A-49D3-B639-8DD4BF085593"><gtr:id>F3A630B1-725A-49D3-B639-8DD4BF085593</gtr:id><gtr:firstName>Everard</gtr:firstName><gtr:surname>Mascarenhas</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=700454"><gtr:id>D763AD72-2E6E-4112-97EE-46386391C030</gtr:id><gtr:title>Market study for diagnostic biosensors</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Market</gtr:grantCategory><gtr:grantReference>700454</gtr:grantReference><gtr:abstractText>Sarissa Biomedical develops &amp;amp; sells microelectronic (enzymatic) biosensors. Its devices are
highly sensitive, selective &amp;amp; able to measure analytes in biological tissues &amp;amp; fluids such as
unprocessed whole blood making them ideal for point of care diagnostics (PoC). Sarissa has
identified a number of diseases where biomarkers have been proposed but the technology to
accurately measure them outside a pathlab does not exist. Sarissa?s solution potentially
provides a very low cost bedside/ PoC solution as an alternative to existing slow, capital
intensive and high-skilled pathlab operation.
The Company is currently working with a number of hospitals &amp;amp; Universities on clinical trials
to validate biomarkers and using Sarissa?s technology to directly measure these biomarkers in
whole blood. Target diseases include stroke, sepsis and foetal hypoxia. Whilst highly
effective therapies exist for these diseases, the critical factor for a positive outcome is early
intervention. Unfortunately current diagnostics for these conditions are slow, expensive and
requiring specialist clinicians. As a result patients regularly have poor outcomes. Sarissa?s
technology has the potential to transform the treatment of these conditions.
The successful adoption of any new medical technology requires a clear understanding of the
clinical pathway, regulatory conditions, health economics and budgetary factors of the various
healthcare provider. This Proof of Market study is aimed at researching these issues to
provide an understanding of the market opportunity and, in particular, where within the
existing clinical pathway adoption is most likely to occur and the regulatory issues that will
need to be addressed. The study will be critical in developing a business and investment plan
to drive future growth of the company.</gtr:abstractText><gtr:fund><gtr:end>2015-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2014-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>15000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">700454</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>